LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Research

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kahabuka C, Mtove G, Nadjm B, Deen JL, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Petro TE, von Seidlein L, Day NPJ, White NJ
Download
Download
Abstract
Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality. We compared parenteral treatment with either artesunate or quinine in African children with severe malaria.
Countries
Democratic Republic of CongoGambiaGhanaKenyaMozambiqueNigeriaRwandaUgandaTanzania, United Republic of_
Subject Area
pediatricsmalaria
DOI
10.1016/S0140-6736(10)61924-1
Published Date
08-Nov-2010
PubMed ID
21062666
Languages
English
Journal
Lancet
Volume / Issue / Pages
Volume 376, Issue 9753
Issue Date
01-Nov-2010
Dimensions Badge